RCC
Les récepteurs des chimiokines C-C (CCRs) sont un groupe de GPCR qui répondent aux chimiokines, des molécules de signalisation qui guident la migration des cellules immunitaires vers les sites d'inflammation ou d'infection. Les CCR jouent un rôle crucial dans les réponses immunitaires, l'inflammation et le développement de diverses maladies, y compris les troubles auto-immuns et le cancer. La modulation de l'activité des CCR est explorée comme une stratégie thérapeutique pour des affections telles que la polyarthrite rhumatoïde, la sclérose en plaques et l'infection par le VIH. Chez CymitQuimica, nous offrons une gamme de modulateurs de CCR de haute qualité pour soutenir vos recherches en immunologie, inflammation et développement thérapeutique.
165 produits trouvés pour "RCC".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
MLN-3897 TFA
MLN-3897 TFA is a potent CCR1 antagonist that inhibits the binding of 125I-MIP-1α to THP-1 cell membranes.Formule :C32H32ClF3N2O6Degré de pureté :99.80%Couleur et forme :SolidMasse moléculaire :633.05BMS-753426
CAS :BMS-753426 is a potent and orally bioavailable antagonist of CCR2 .Formule :C25H33F3N6O2Couleur et forme :SolidMasse moléculaire :506.574CMKLR1 antagonist 1
CMKLR1 antagonist 1 (compound S-26d) is a potent, orally active antagonist of the chemokine-like receptor 1 (CMKLR1), exhibiting a pIC50 of 7.44 in hCMKLR1-Couleur et forme :Odour SolidPlozalizumab
CAS :Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study ofDegré de pureté :96.4%Couleur et forme :Transparent LiquidMasse moléculaire :146.02 kDa (Predicted)VZMC013
VZMC013 is a potent chemical probe targeting the MOR-CCR5 heterodimer, effectively inhibiting HIV-1 entry exacerbated by opioid compounds. It exhibits nanomolar binding affinity to both MOR and CCR5, inhibits CCL5-activated calcium mobilization, and significantly enhances anti-HIV-1BaL activity compared to previously reported bivalent ligands. In TZM-bl cells co-expressing CCR5 and MOR, VZMC013 demonstrates greater inhibition of viral infection than in cells expressing only CCR5. Additionally, VZMC013 blocks HIV-1 entry into peripheral blood mononuclear cells (PBMC) in a concentration-dependent manner and more effectively inhibits opioid-accelerated HIV-1 entry in phytohemagglutinin-activated PBMC than in opioid-free environments.Formule :C65H92F2N10O10Masse moléculaire :1211.48Bertilimumab
CAS :Bertilimumab (CAT 213; iCo-008), humanized anti-eotaxin-1 mAb, inhibits eosinophil chemotaxis/activation for allergic disease research.Degré de pureté :95%Couleur et forme :LiquidMasse moléculaire :~148 kDaWAY-639418
CAS :WAY-639418 has potential anti-inflammatory and anti-HIV activity and can be used to study CCR5-mediated inflammatory and immunomodulatory diseases.Formule :C17H16ClN5Degré de pureté :99.89%Couleur et forme :Yellow SolidMasse moléculaire :325.795Chemokine Inhibitor Library
A unique collection of xnum chemokines or chemokine receptors targeted compounds for high throughput and high content screening;Couleur et forme :Odour SolidPF-232798
CAS :PF-232798 is a second generation oral CCR5 antagonist with potent broad-spectrum anti-HIV-1 activity.Formule :C29H40FN5O2Couleur et forme :SolidMasse moléculaire :509.66SQA1
CAS :SQA1 is a derivative of a phthalamide (SQA) and acts as a CCR6 antagonist with a Kd of 250 nM, as well as a CXCR2 inhibitor. It occupies an intracellular pocket that overlaps with the G protein binding site, stabilizing the pocket's closed conformation.Formule :C22H26N4O5Couleur et forme :SolidMasse moléculaire :426.47CCR8 antagonist 1
CAS :CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.Formule :C26H29N3O5SDegré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :495.591Met-RANTES,human,acetate
Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.Couleur et forme :Odour SolidTBK1 degrader-4
TBK1degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. It effectively inhibits cyst growth, reduces inflammation, and lowers levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1degrader-4 shows potential for research in autosomal dominant polycystic kidney disease (ADPKD).Couleur et forme :Odour SolidINCB 3284 dimesylate
CAS :INCB 3284 dimesylate: oral CCR2 antagonist, blocks MCP-1/hCCR2 binding (IC50: 3.7 nM), potential in acute liver failure research.Formule :C28H39F3N4O10S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :712.76PROTAC CCR9 Degrader 1
PROTAC CCR9 Degrader 1 is a PROTAC-based degrader specifically targeting CCR9. It functions by recruiting the VHL E3 ligase, leading to the ubiquitination and proteasomal degradation of CCR9, thereby reducing its intracellular levels. The compound has a Ki value of 78.0 nM for human CCR9. Additionally, PROTAC CCR9 Degrader 1 modulates GPCR activity by binding to the allosteric site within CCR9 and is applicable in research related to Crohn's disease.CCR4 antagonist 3 hydrochloride
CAS :Orally active CCR4 antagonist 3 hydrochloride with potent selectivity, IC50s: 22/50 nM; has antitumor properties.Formule :C24H27Cl2N7O·xHClCouleur et forme :SolidCCR6 antagonist 2
CCR6 antagonist2 (Compound 20c) acts as a CCR6 antagonist with a Ki of 1.1 nM. It inhibits CCL20-induced calcium influx with an IC50 of 4.9 nM and suppresses the chemotactic migration of CCR6+ T cells with an IC50 of 190 nM.Formule :C19H24N4O4Couleur et forme :SolidMasse moléculaire :372.42CCR4 antagonist 3
CAS :Orally active CCR4 antagonist with piperidinyl-azetidine; IC50: 22 nM (calcium flux), 50 nM (CTX); antitumor effects.Formule :C24H27Cl2N7OCouleur et forme :SolidMasse moléculaire :500.423CCR2 antagonist 1
CAS :CCR2 antagonist 1 is a high-affinity and long-residence-time antagonist of CCR2 (Ki: 2.4 nM).Formule :C28H32BrF3N2OCouleur et forme :SolidMasse moléculaire :549.466NI-0701
NI-0701 is a humanized antibody targeting CCL5/RANTES.Degré de pureté :95.4% (SDS-PAGE); 99.4% (SEC-HPLC) - 95.4% (SDS-PAGE); 99.4% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :144.83 kDa (Predicted)
